Re:SARS-CoV-2 variant A.30 is heavily mutated and evades vac...
by 323 on Tuesday October 26, 2021 @04:28PM
(#29005847)
Why not just update the vaccine with the corresponding sequence from the Delta variant? Isn't the Delta variant today a better baseline than the ancestral virus?
Or do a mix - first shot ancestral, second shot Delta.
Re:SARS-CoV-2 variant A.30 is heavily mutated and evades vac...
by nextos on Tuesday October 26, 2021 @04:52PM
(#29006105)
I think this is the logical thing to do, but now there are two new roadblocks clinical trials have to face:
* It's hard to recruit non-vaccinated participants
* There will be safety issues to address on people that have received multiple shots and / or designed against different strains
I think the quick (and overly simplistic) answer to this question is that models (e.g. convolutional networks) that predict which chunks of viral (or human) proteins are displayed to immune cells (HLA presentation), along with other kinds of models (like those predicting crossreactivity of T cell receptors against mutated epitopes) are really primitive (mostly because of low quality training datasets, it's not really a hard problem like e.g. protein folding).
Hence, rushing a new vaccine is not easy as there is a lot of labwork to do. As a matter of fact, all COVID vaccine designs had essentially the same payload (the whole spike protein). Modern subunit vaccines would typically include only little chunks of the spike (to increase efficiency and avoid side effects). But this was not trivial to do quickly without good in silico models.